Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 491

Sort by

Sort Order Select

Journal Articles

Minimal Residual Disease (MRD) Assessment in the ECOG1411 Randomized Phase 2 Trial of Front-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma (MCL)

Mitchell Smith, MD PhD, Opeyemi Jegede, PhD, Samir Parekh, MD, Curtis A. Hanson, MD, Peter Martin, FRCPC, MD MS, Brian G. Till, MD, Michael Crump, MD FRCPC, John P. Leonard, MD, Jonathan W. Friedberg, MD, Brad S. Kahl, MD, Thomas E. Witzig, MD

Blood (2019) 134 (Supplement_1): 751.

https://doi.org/10.1182/blood-2019-129323

Published: 2019

Journal Articles

Detectable Circulating Tumor DNA 28 Days after the CD19 CAR T-Cell Therapy, Axicabtagene Ciloleucel, Is Associated with Poor Outcomes in Patients with Diffuse Large B-Cell Lymphoma

Matthew J. Frank, MD PhD, Nasheed Hossain, MD, Ali Bukhari, MD, Erin Dean, MD, Jay Y. Spiegel, MDFRCPC, Gursharan K. Claire, MPH, Ilan M. Kirsch, Allison P. Jacob, Chelsea D Mullins, BS, Lik Wee Lee, PhD, Katherine A. Kong, Juliana Craig, BA, Crystal L. Mackall, MD, Aaron P. Rapoport, Saurabh Dahiya, MD, Frederick L. Locke, MD, David B Miklos, MD PhD

Blood (2019) 134 (Supplement_1): 884.

https://doi.org/10.1182/blood-2019-132057

Published: 2019

Journal Articles

Long-Term Follow-up of Follicular Lymphoma (FL) Patients (pts) Demonstrating Undetectable Minimal Residual Disease (MRD) Using a Next-Generation Based DNA Assay: Support for FL As a Curable Disease

Maryam Sarraf Yazdy, MD, Umair Jarral, MD, Chao Yin, MD, Frank Kuhr, PhD, Allison P. Jacob, Bruce D. Cheson, MD

Blood (2019) 134 (Supplement_1): 2813.

https://doi.org/10.1182/blood-2019-127262

Published: 2019

Journal Articles

Macrophages Promote DNA Repair of Double Strand Break in Multiple Myeloma Cells By Non-Homologous End Joining(NHEJ), Nevertheless Decrease Its Accuracy

Mengmeng Dong, Enfan Zhang, Haimeng Yan, MD, Ruyi Xu, He Huang, Anyong Xie, Zhen Cai, MD PhD

Blood (2019) 134 (Supplement_1): 3087.

https://doi.org/10.1182/blood-2019-126753

Published: 2019

Journal Articles

Circulating Tumor Cells (CTCs) for Comprehensive and Multiregional Non-Invasive Genetic Characterization of Multiple Myeloma (MM)

Blood (2019) 134 (Supplement_1): 3064.

https://doi.org/10.1182/blood-2019-126527

Published: 2019

Journal Articles

A Multi-Center Epidemiological and Prognostic Analysis of Cytogenetic Abnormalities in a Cohort of 1015 Chinese Patients with Newly-Diagnosed Multiple Myeloma

Fengyan Jin, MD PhD, Guangxun Gao, MD, Yujun Dong, MD, Chunrui Li, MD PhD, Wenrong Huang, Limo Zhang, MD, Qiang Zhu, MD, Ruifeng Yuan, MD, Li Xu, MD, Yanjie Xu, MD, Qian Xu, Shaji K. Kumar, MD, Yun Dai, MD

Blood (2019) 134 (Supplement_1): 3094.

https://doi.org/10.1182/blood-2019-132076

Published: 2019

Journal Articles

A Fast and Accurate Diagnostic Method for Ph-like ALL Using the Ncounter System

Kensuke Sasaki, MD, Kohta Miyawaki, MD PhD, Yuichiro Semba, MD PhD, Koji Kato, MD PhD, Jumpei Nogami, PhD, Takeshi Sugio, MD PhD, Toshihiro Miyamoto, MD PhD, Yoshikiyo Ito, MD PhD, Koji Nagafuji, MD PhD, Takahiro Maeda, MD PhD, Koichi Akashi, MD PhD

Blood (2019) 134 (Supplement_1): 375.

https://doi.org/10.1182/blood-2019-129625

Published: 2019

Journal Articles

Therapy of Paediatric B-ALL with a Fast Off Rate CD19 CAR Leads to Enhanced Expansion and Prolonged CAR T Cell Persistence in Patients with Low Bone Marrow Tumour Burden, and Is Associated with a Favourable Toxicity Profile

Blood (2019) 134 (Supplement_1): 225.

https://doi.org/10.1182/blood-2019-125009

Published: 2019

Journal Articles

Combined EZH2 and BCL2 Inhibitors As Precision Therapy for Genetically Defined DLBCL Subtypes

Destini Gibbs, Herman Van Besien, BA, Stephenson Regan, Ankur Singh, PhD, Matthew Teater, Ethel Cesarman, MD PhD, Ari Melnick, MD, Lisa Giulino Roth, MD

Blood (2019) 134 (Supplement_1): 304.

https://doi.org/10.1182/blood-2019-126790

Published: 2019

Journal Articles

Clinical, Immunophenotypic and Genetic Characteristics of Aggressive (non-Burkitt) B-Cell Lymphoma in a Real Life Cohort

Blood (2019) 134 (Supplement_1): 4122.

https://doi.org/10.1182/blood-2019-123259

Published: 2019

Journal Articles

Oncogenic MAF in Co-Operation with IRF4 Confers Extensive Chromatin Re-Arrangement in Plasma Cells and Generates 'Neo-Enhancers' That Regulate Genes Critical for Myeloma Biology

Alexia Katsarou, Nikolaos Trasanidis, Jaime Alvarez-Benayas, Foteini Papaleonidopoulou, Keren Keren, Ioannis V. Kostopoulos, Kanagaraju Ponnusamy, Xiaolin Xiao, Niklas Feldhahn, Irene Roberts, Evdoxia Hatjiharissi, Maria Papaioannou, Ian Sudbery, Aristeidis Chaidos, Valentina S Caputo, Anastasios Karadimitris

Blood (2019) 134 (Supplement_1): 3783.

https://doi.org/10.1182/blood-2019-122371

Published: 2019

Journal Articles

P53 Pathway Activation Mediated High c-MAF Expression Is Associated with Overall and Post-Progression Survival in Multiple Myeloma

Blood (2019) 134 (Supplement_1): 4330.

https://doi.org/10.1182/blood-2019-125172

Published: 2019

Journal Articles

The CCND1 870G Risk Allele Is Enriched in African Individuals with Plasma Cell Dyscrasias

Linda B Baughn, PhD, Zhou Li, MS, Kathryn E. Pearce, Celine M. Vachon, PhD, Mei-Yin Polley, PhD, Jonathan J Keats, PhD, Eran Elhaik, PhD, Michael L. Baird, PhD, Terry Therneau, PhD, James R. Cerhan, MD PhD, P. Leif Bergsagel, MD, Angela Dispenzieri, MD, S.Vincent Rajkumar, MD, Yan Asmann, PhD, Shaji K. Kumar, MD

Blood (2019) 134 (Supplement_1): 4362.

https://doi.org/10.1182/blood-2019-124979

Published: 2019

Journal Articles

Significance of Modified Risk Stratification Msmart 3.0 and Autologous Stem Cell Transplantation for Patients with Newly Diagnosed Multiple Myeloma

Andrey Garifullin, MD, Sergei Voloshin, MD PhD, Vasily Shuvaev, MD, Irina Martynkevich, MD PhD, Elizaveta Kleina, Alexander Chechetkin, Stanislav Bessmeltcev, Anastasiya Kuzyaeva, Alexander Sсhmidt, Alexey Kuvshinov, MD, Irina Pavlova

Blood (2019) 134 (Supplement_1): 5593.

https://doi.org/10.1182/blood-2019-130092

Published: 2019

Journal Articles

Impact of Targeted Immunotherapies and Novel Cytogenetic and Clinical Risk Groups on Outcome after Allogeneic Hematopoietic Stem Cell Transplant (AlloHCT) for Acute Lymphoblastic Leukemia (ALL): The Mayo Clinic Cohort

Zaid Abdel Rahman, MD, Michael G. Heckman, Kevin C. Miller, BS, Patricia Greipp, DO, Matthew R Spiegel, Sharad Khurana, MDMSc, Hassan B. Alkhateeb, MD, Mrinal M Patnaik, MDMBBS, Lisa Z. Sproat, MD, Liuyan Jiang, Vivek Roy, MD, Mark Litzow, MD, Mohamed A Kharfan-Dabaja, MDMBA, William J Hogan, MB, BCh, James M. Foran, MD

Blood (2019) 134 (Supplement_1): 2588.

https://doi.org/10.1182/blood-2019-122068

Published: 2019

Journal Articles

Intensive Chemotherapy Along with Aggressive Supportive Care Can Spare Stem Cell Transplantation in a Subset of Patients without Compromising an Outcome in Infants with Acute Lymphoblastic Leukemia; A Report from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) Trial MLL-10

Blood (2019) 134 (Supplement_1): 2626.

https://doi.org/10.1182/blood-2019-121328

Published: 2019

Journal Articles

Phase I Study of Escalating Doses of Carfilzomib with Hyper-CVAD in Patients with Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma

Samantha C Fisch, BS, Brian A Jonas, MD PhD, Joseph Tuscano, MD, Aaron Seth Rosenberg, MD, Rasmus T Hoeg, MD, Mehrdad Abedi, MD

Blood (2019) 134 (Supplement_1): 3884.

https://doi.org/10.1182/blood-2019-121991

Published: 2019

Journal Articles

Moffitt Cancer Center 2-Year Single-Institution Experience with Next-Generation Sequencing Minimal Residual Disease Detection: Clinical Utility, Application, and Correlation with Outcomes in Plasma Cell and Lymphoid Malignancies

Mohammad O Hussaini, MD, Jaya Srivastava, PhD, Lik Wee Lee, PhD, Taiga Nishihori, MD, Bijal Shah, MD, Melissa Alsina, MD, Rachid Baz, MD, Javier Pinilla Ibarz, MD PhD, Kenneth H. Shain, MD PhD

Blood (2019) 134 (Supplement_1): 4654.

https://doi.org/10.1182/blood-2019-129846

Published: 2019

Journal Articles

Deciphering the Chronology of Copy Number Alterations in Multiple Myeloma (MM): What Comes First?

Anil Aktas Samur, PhD, Mehmet Kemal Samur, PhD, Stephane Minvielle, PhD, Florence Magrangeas, PhD, Masood A. Shammas, PhD, Mariateresa Fulciniti, PhD, Michel Attal, MD PhD, Philippe Moreau, Kenneth Anderson, MD, Giovanni Parmigiani, Hervé Avet-Loiseau, MD PhD, Nikhil Munshi, MD

Blood (2018) 132 (Supplement 1): 3171.

https://doi.org/10.1182/blood-2018-99-120101

Published: 2018

Journal Articles

Immunoglobulin Lambda Translocations Identify Poor Outcome and IMiD Resistance in Multiple Myeloma and Co-Occur with Hyperdiploidy

Benjamin G Barwick, PhD, Paola Neri, MD, Nizar Bahlis, MD, Ajay K Nooka, MDMPH, Jonathan L Kaufman, MD, Vikas A. Gupta, MD PhD, Daniel Auclair, PhD, Jonathan J Keats, PhD, Sagar Lonial, MD, Paula M Vertino, PhD, Lawrence H. Boise, PhD

Blood (2018) 132 (Supplement 1): 405.

https://doi.org/10.1182/blood-2018-99-113585

Published: 2018

NARROW

Minimal Residual Disease (MRD) Assessment in the ECOG1411 Randomized Phase 2 Trial of Front-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma (MCL)

Detectable Circulating Tumor DNA 28 Days after the CD19 CAR T-Cell Therapy, Axicabtagene Ciloleucel, Is Associated with Poor Outcomes in Patients with Diffuse Large B-Cell Lymphoma

Long-Term Follow-up of Follicular Lymphoma (FL) Patients (pts) Demonstrating Undetectable Minimal Residual Disease (MRD) Using a Next-Generation Based DNA Assay: Support for FL As a Curable Disease

Macrophages Promote DNA Repair of Double Strand Break in Multiple Myeloma Cells By Non-Homologous End Joining(NHEJ), Nevertheless Decrease Its Accuracy

Circulating Tumor Cells (CTCs) for Comprehensive and Multiregional Non-Invasive Genetic Characterization of Multiple Myeloma (MM)

A Multi-Center Epidemiological and Prognostic Analysis of Cytogenetic Abnormalities in a Cohort of 1015 Chinese Patients with Newly-Diagnosed Multiple Myeloma

A Fast and Accurate Diagnostic Method for Ph-like ALL Using the Ncounter System

Therapy of Paediatric B-ALL with a Fast Off Rate CD19 CAR Leads to Enhanced Expansion and Prolonged CAR T Cell Persistence in Patients with Low Bone Marrow Tumour Burden, and Is Associated with a Favourable Toxicity Profile

Combined EZH2 and BCL2 Inhibitors As Precision Therapy for Genetically Defined DLBCL Subtypes

Clinical, Immunophenotypic and Genetic Characteristics of Aggressive (non-Burkitt) B-Cell Lymphoma in a Real Life Cohort

Oncogenic MAF in Co-Operation with IRF4 Confers Extensive Chromatin Re-Arrangement in Plasma Cells and Generates 'Neo-Enhancers' That Regulate Genes Critical for Myeloma Biology

P53 Pathway Activation Mediated High c-MAF Expression Is Associated with Overall and Post-Progression Survival in Multiple Myeloma

The CCND1 870G Risk Allele Is Enriched in African Individuals with Plasma Cell Dyscrasias

Significance of Modified Risk Stratification Msmart 3.0 and Autologous Stem Cell Transplantation for Patients with Newly Diagnosed Multiple Myeloma

Impact of Targeted Immunotherapies and Novel Cytogenetic and Clinical Risk Groups on Outcome after Allogeneic Hematopoietic Stem Cell Transplant (AlloHCT) for Acute Lymphoblastic Leukemia (ALL): The Mayo Clinic Cohort

Intensive Chemotherapy Along with Aggressive Supportive Care Can Spare Stem Cell Transplantation in a Subset of Patients without Compromising an Outcome in Infants with Acute Lymphoblastic Leukemia; A Report from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) Trial MLL-10

Phase I Study of Escalating Doses of Carfilzomib with Hyper-CVAD in Patients with Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma

Moffitt Cancer Center 2-Year Single-Institution Experience with Next-Generation Sequencing Minimal Residual Disease Detection: Clinical Utility, Application, and Correlation with Outcomes in Plasma Cell and Lymphoid Malignancies

Deciphering the Chronology of Copy Number Alterations in Multiple Myeloma (MM): What Comes First?

Immunoglobulin Lambda Translocations Identify Poor Outcome and IMiD Resistance in Multiple Myeloma and Co-Occur with Hyperdiploidy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only